Considering previous reports showing that anti-CTLA-4 mainly targets lymph node T cells and increases tumor infiltration by new effector T cells (Ribas et al, 2010; Wei et al, 2019), intratumoral T cell dysfunction reflected by sCD27 could be less associated with resistance to the anti-CTLA-4 + anti-PD-1 combination. This evidence concerns the gene CTLA4 and neoplasm.